Back

Vutrisiran is associated with preservation of intrinsic capacity and healthy ageing in patients with transthyretin amyloidosis with cardiomyopathy: post hoc analysis of HELIOS-B

30 August 2026 (08:15 - 08:25)
Organised by: Logo
Congress Presentation Part of: Approaching heart failure therapy from all angles Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Olivier Lairez

University Hospital of Toulouse, Toulouse (France)

5 More presentations in this session

Presentation thumbnail
Machine learning approaches for the prediction of 1-year mortality after heart transplantation: a systematic review and meta-analysis
Doctor D. Mutahar (Gold Coast, AU)
Abstract Slides Video
Presentation thumbnail
Empagliflozin attenuates adverse outcomes of acute ischemic heart failure by targeting NLRP3/IL1β mediated macrophage polarization and inflammatory response
Mr G. Zhou (Chongqing, CN)
Abstract Slides Video
Presentation thumbnail
Cardiac rehabilitation referral in heart failure units: clinical profile and outcomes from the Spanish National SEC-EXCELENTE-IC Registry
Doctor A. Esteban Fernandez (Leganes, ES)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes and one-year survival in heart transplant recipients from donors after circulatory death versus brain death: a meta-analysis of current evidence
Assistant Professor D. Garcia Maldonado (Ciudad de Mexico, MX)
Abstract Slides Video
Presentation thumbnail
Effectiveness of RSV vaccine against cardio-respiratory hospitalizations in heart failure: a prespecified analysis of the DAN-RSV trial
Doctor K. Skaarup (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Approaching heart failure therapy from all angles
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of disease-modifying treatment on functional capacity in patients with ATTR-CA: pathophysiological insights from iCPET
20 May 2023
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials
30 August 2021
thumbnail
Congress Presentation
Highlights from HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
31 August 2024
thumbnail
Congress Presentation
Effect of RNAi therapeutics patisiran and vutrisiran on orthostatic hypotension due to dysautonomia in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources